These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 32995773)

  • 1. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.
    He L; Lin X; Wang Y; Abraham C; Sou C; Ngo T; Zhang Y; Wilson IA; Zhu J
    bioRxiv; 2021 Apr; ():. PubMed ID: 32995773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.
    He L; Lin X; Wang Y; Abraham C; Sou C; Ngo T; Zhang Y; Wilson IA; Zhu J
    Sci Adv; 2021 Mar; 7(12):. PubMed ID: 33741598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants.
    Zhang YN; Paynter J; Sou C; Fourfouris T; Wang Y; Abraham C; Ngo T; Zhang Y; He L; Zhu J
    bioRxiv; 2021 Sep; ():. PubMed ID: 33791704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants.
    Zhang YN; Paynter J; Sou C; Fourfouris T; Wang Y; Abraham C; Ngo T; Zhang Y; He L; Zhu J
    Sci Adv; 2021 Oct; 7(43):eabj3107. PubMed ID: 34669468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extraordinary Titer and Broad Anti-SARS-CoV-2 Neutralization Induced by Stabilized RBD Nanoparticles from Strain BA.5.
    Wang Z; Zhang B; Ou L; Qiu Q; Wang L; Bylund T; Kong WP; Shi W; Tsybovsky Y; Wu L; Zhou Q; Chaudhary R; Choe M; Dickey TH; El Anbari M; Olia AS; Rawi R; Teng IT; Wang D; Wang S; Tolia NH; Zhou T; Kwong PD
    Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38250850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.
    Kang YF; Sun C; Zhuang Z; Yuan RY; Zheng Q; Li JP; Zhou PP; Chen XC; Liu Z; Zhang X; Yu XH; Kong XW; Zhu QY; Zhong Q; Xu M; Zhong NS; Zeng YX; Feng GK; Ke C; Zhao JC; Zeng MS
    ACS Nano; 2021 Feb; 15(2):2738-2752. PubMed ID: 33464829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery.
    Liu C; Wang L; Merriam JS; Shi W; Yang ES; Zhang Y; Chen M; Kong WP; Cheng C; Tsybovsky Y; Stephens T; Verardi R; Leung K; Stein C; Olia AS; Harris DR; Choe M; Zhang B; Graham BS; Kwong PD; Koup RA; Pegu A; Mascola JR
    NPJ Vaccines; 2023 Aug; 8(1):111. PubMed ID: 37553406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines.
    Dickey TH; Ma R; Orr-Gonzalez S; Ouahes T; Patel P; McAleese H; Butler B; Eudy E; Eaton B; Murphy M; Kwan JL; Salinas ND; Holbrook MR; Lambert LE; Tolia NH
    Cell Rep; 2023 Mar; 42(3):112266. PubMed ID: 36943870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of spike receptor-binding domain nanoparticle as a vaccine candidate against SARS-CoV-2 infection in ferrets.
    Kim YI; Kim D; Yu KM; Seo HD; Lee SA; Casel MAB; Jang SG; Kim S; Jung W; Lai CJ; Choi YK; Jung JU
    bioRxiv; 2021 Jan; ():. PubMed ID: 33532767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
    Walls AC; Fiala B; Schäfer A; Wrenn S; Pham MN; Murphy M; Tse LV; Shehata L; O'Connor MA; Chen C; Navarro MJ; Miranda MC; Pettie D; Ravichandran R; Kraft JC; Ogohara C; Palser A; Chalk S; Lee EC; Guerriero K; Kepl E; Chow CM; Sydeman C; Hodge EA; Brown B; Fuller JT; Dinnon KH; Gralinski LE; Leist SR; Gully KL; Lewis TB; Guttman M; Chu HY; Lee KK; Fuller DH; Baric RS; Kellam P; Carter L; Pepper M; Sheahan TP; Veesler D; King NP
    Cell; 2020 Nov; 183(5):1367-1382.e17. PubMed ID: 33160446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2.
    Walls AC; Fiala B; Schäfer A; Wrenn S; Pham MN; Murphy M; Tse LV; Shehata L; O'Connor MA; Chen C; Navarro MJ; Miranda MC; Pettie D; Ravichandran R; Kraft JC; Ogohara C; Palser A; Chalk S; Lee EC; Kepl E; Chow CM; Sydeman C; Hodge EA; Brown B; Fuller JT; Dinnon KH; Gralinski LE; Leist SR; Gully KL; Lewis TB; Guttman M; Chu HY; Lee KK; Fuller DH; Baric RS; Kellam P; Carter L; Pepper M; Sheahan TP; Veesler D; King NP
    bioRxiv; 2020 Aug; ():. PubMed ID: 32817941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffolds.
    Halfmann PJ; Castro A; Loeffler K; Frey SJ; Chiba S; Kawaoka Y; Kane RS
    Bioeng Transl Med; 2021 Sep; 6(3):e10253. PubMed ID: 34589610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous DNA-prime/protein-boost immunization with a monomeric SARS-CoV-2 spike antigen redundantizes the trimeric receptor-binding domain structure to induce neutralizing antibodies in old mice.
    Pflumm D; Seidel A; Klein F; Groß R; Krutzke L; Kochanek S; Kroschel J; Münch J; Stifter K; Schirmbeck R
    Front Immunol; 2023; 14():1231274. PubMed ID: 37753087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Component Multilayered Self-Assembling Protein Nanoparticles Displaying Extracellular Domains of Matrix Protein 2 as a Pan-influenza A Vaccine.
    Braz Gomes K; Zhang YN; Lee YZ; Eldad M; Lim A; Ward G; Auclair S; He L; Zhu J
    ACS Nano; 2023 Dec; 17(23):23545-23567. PubMed ID: 37988765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bioengineered pseudovirus nanoparticle displaying SARS-CoV 2 RBD fully protects mice from mortality and weight loss caused by SARS-CoV 2 challenge.
    Xia M; López K; Vago FS; Huang P; Auguste DI; Jiang W; Auguste AJ; Tan M
    Biotechnol J; 2023 Oct; 18(10):e2300130. PubMed ID: 37300425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys.
    Li H; Guo L; Zheng H; Li J; Zhao X; Li J; Liang Y; Yang F; Zhao Y; Yang J; Xue M; Zuo Y; Zhou J; Chen Y; Yang Z; Li Y; Jin W; Shi H; He Z; Li Q; Liu L
    Bioconjug Chem; 2021 May; 32(5):1034-1046. PubMed ID: 33951913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.